In vitro study on the role of SOX9 in trastuzumab resistance of adenocarcinoma of the esophagogastric junction

  • Authors:
    • Yingcai Hong
    • Huaisheng Chen
    • Zhanpeng Rao
    • Bin Peng
    • Hong Hu
    • Shaolin Lin
    • Zhenglei Xu
  • View Affiliations

  • Published online on: January 12, 2018     https://doi.org/10.3892/etm.2018.5744
Metrics: HTML 0 views | PDF 0 views     Cited By: 0 citations

Abstract

Trastuzumab is recommended for the treatment of human epidermal growth factor receptor 2‑positive adenocarcinoma of the esophagogastric junction (AEG) in combination with chemotherapy; however, drug resistance has severely affected its clinical application. The present study aimed to investigate the effect of sex determining region Y‑box 9 (SOX9), a prognostic marker in adjuvant oncological settings, on AEG cell proliferation and apoptosis in the presence or absence of trastuzumab. Furthermore, the molecular mechanism underlying the role of SOX9 in trastuzumab resistance was explored. ESO26 cells were treated with various concentrations of trastuzumab, and trastuzumab induced SOX9 expression in a concentration‑dependent manner, as determined by reverse transcription‑quantitative polymerase chain reaction and western blotting analyses. Transfection of ESO26 cells with SOX9 small interfering RNA was conducted to knock down SOX9 expression, and the results of MTT and flow cytome­try assays demonstrated that SOX9 knockdown sensitized ESO26 cells to trastuzumab by inhibiting cell proliferation and enhancing cell apoptosis. In addition, it was observed that the trastuzumab‑induced phosphorylation of AKT was suppressed by SOX9 knockdown. In conclusion, the present study demonstrated that SOX9 participated in trastuzumab resistance by affecting cell proliferation and apoptosis, and indicated that SOX9 may exert its effect on trastuzumab resistance via activation of the phosphatidylinositol-3-kinase/AKT signaling pathway. This study identified a novel mechanism underlying trastuzumab resistance in vitro and may be useful in improving the efficacy of trastuzumab treatment.

Related Articles

Journal Cover

Print ISSN: 1792-0981
Online ISSN:1792-1015

2016 Impact Factor: 1.261
Ranked #50/128 Medicine Research and Experimental
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Hong, Y., Chen, H., Rao, Z., Peng, B., Hu, H., Lin, S., & Xu, Z. (1899). In vitro study on the role of SOX9 in trastuzumab resistance of adenocarcinoma of the esophagogastric junction. Experimental and Therapeutic Medicine, 0, 0-0. https://doi.org/10.3892/etm.2018.5744
MLA
Hong, Y., Chen, H., Rao, Z., Peng, B., Hu, H., Lin, S., Xu, Z."In vitro study on the role of SOX9 in trastuzumab resistance of adenocarcinoma of the esophagogastric junction". Experimental and Therapeutic Medicine 0.0 (1899): 0-0.
Chicago
Hong, Y., Chen, H., Rao, Z., Peng, B., Hu, H., Lin, S., Xu, Z."In vitro study on the role of SOX9 in trastuzumab resistance of adenocarcinoma of the esophagogastric junction". Experimental and Therapeutic Medicine 0, no. 0 (1899): 0-0. https://doi.org/10.3892/etm.2018.5744